Edition:
India

Esperion Therapeutics Inc (ESPR.OQ)

ESPR.OQ on NASDAQ Stock Exchange Global Market

55.81USD
22 Nov 2017
Change (% chg)

$0.23 (+0.41%)
Prev Close
$55.58
Open
$56.01
Day's High
$56.70
Day's Low
$55.21
Volume
118,359
Avg. Vol
215,553
52-wk High
$57.67
52-wk Low
$10.31

Chart for

About

Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the... (more)

Overall

Beta: 2.67
Market Cap(Mil.): $1,444.21
Shares Outstanding(Mil.): 25.69
Dividend: --
Yield (%): --

Financials

BRIEF-Esperion Therapeutics Q3 loss per share $1.86‍​

* Esperion provides bempedoic acid franchise development program updates; reports third quarter 2017 financial results

07 Nov 2017

BRIEF-Esperion announces initiation of pivotal late stage study for bempedoic acid

* Esperion announces initiation of pivotal late stage study for the bempedoic acid / ezetimibe combination pill

07 Nov 2017

BRIEF-Esperion Therapeutics - Phase 3 results for bempedoic acid expected in Q2, Q3 2018

* Esperion Therapeutics- bempedoic acid top-line results from studies 1, 3 and 4 are expected in Q2 2018, results from study 2 expected in Q3 2018

03 Oct 2017

BRIEF-Meditor Group Ltd reports 8.2 pct passive stake in Esperion Therapeutics Inc

* Meditor Group Ltd reports 8.2 percent passive stake in Esperion Therapeutics Inc as on Aug 10 - SEC filing​ Source text (http://bit.ly/2x6jGbc) Further company coverage:

21 Aug 2017

BRIEF-Esperion announces proposed public offering of common stock

* Esperion announces proposed public offering of common stock

09 Aug 2017

BRIEF-Co announces positive top-line results from Phase 2 study of Bempedoic Acid / Ezetimibe combination plus Atorvastatin​

* Says Esperion announces positive top-line results from Phase 2 study of Bempedoic Acid / Ezetimibe combination plus Atorvastatin​

08 Aug 2017

BRIEF-Esperion reports initiation of phase 2 study of bempedoic acid added-on to a pcsk9 inhibitor

* Esperion announces initiation of phase 2 study of bempedoic acid added-on to a pcsk9 inhibitor

27 Jul 2017

Earnings vs. Estimates